HCMT/MM2401: Ph2 study of Selinexor + bispecific antibody for RRMM (Multiple Myeloma) - Clinical Trial

What is the Purpose of this Study?

The purpose of this study is to find out if combining a bispecific antibody with a drug called selinexor (XPOVIO) is a safe and effective option for multiple myeloma patients whose disease has returned after treatment or did not adequately respond to treatment.

What is the Condition Being Studied?

Relapsed/Refractory Multiple Myeloma (RRMM)

Who Can Participate in the Study?

Adults ages 18+ who:

Are diagnosed with multiple myeloma
Have disease that returned after treatment or did not respond to treatment

For more information, contact the study team at kara.bonneau@duke.edu.

What is Involved?

If you choose take part in this study, you will receive the study drug selinexor, along with bispecific antibodies that you would already be taking, for 12 months. Selinexor (XPOVIO) is approved by the U.S. Food and Drug Administration (FDA) for use in certain patients with RRMM, who have received at least 4 prior medications and whose disease is no longer responding to certain types of medication. As part of this study, you will have tests, exams, and procedures done as part of your normal care and for research.